Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit
10.1007/s00262-021-03075-3
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
SPRINGER
2023
|
| Subjects: | |
| Online Access: | https://scholarbank.nus.edu.sg/handle/10635/239112 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | National University of Singapore |
| Language: | English |
| id |
sg-nus-scholar.10635-239112 |
|---|---|
| record_format |
dspace |
| spelling |
sg-nus-scholar.10635-2391122024-11-15T10:30:25Z Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit Nickles, Emily Dharmadhikari, Bhushan Li, Yating Walsh, Robert J Koh, Liang Piu Poon, Michelle Tan, Lip Kun Wang, Ling-Zhi Ang, Yvonne Asokumaran, Yugarajah Chong, Wan Qin Huang, Yiqing Loh, Kwok Seng Tay, Joshua Soo, Ross Koh, Mickey Ho, Liam Pock Chan, Marieta Niam, Madelaine Soh, Melissa Luah, Yen Hoon Lim, Chwee Ming Kaliaperumal, Nivashini Au, Veonice B Talib, Najwa Binte Said Nasir Sng, Reina Connolly, John E Goh, Boon Cher Schwarz, Herbert MEDICINE PHYSIOLOGY MICROBIOLOGY AND IMMUNOLOGY DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) CANCER SCIENCE INSTITUTE OF SINGAPORE BIOMED INST FOR GLOBAL HEALTH RES & TECH OTOLARYNGOLOGY DUKE-NUS MEDICAL SCHOOL PATHOLOGY Assoc Prof Herbert Schwarz Science & Technology Life Sciences & Biomedicine Oncology Immunology Nasopharyngeal carcinoma CD137L-DC Dendritic cell immunotherapy EBV Phase 1 clinical trial CD137 LIGAND T-CELLS LYMPHOCYTE-ACTIVATION PHASE-II MONOCYTE IMMUNOTHERAPY RECEPTOR MEMBER DIFFERENTIATION PROLIFERATION 10.1007/s00262-021-03075-3 CANCER IMMUNOLOGY IMMUNOTHERAPY 71 6 1531-1543 2023-05-02T09:15:37Z 2023-05-02T09:15:37Z 2021-10-18 2023-05-02T03:44:21Z Article Nickles, Emily, Dharmadhikari, Bhushan, Li, Yating, Walsh, Robert J, Koh, Liang Piu, Poon, Michelle, Tan, Lip Kun, Wang, Ling-Zhi, Ang, Yvonne, Asokumaran, Yugarajah, Chong, Wan Qin, Huang, Yiqing, Loh, Kwok Seng, Tay, Joshua, Soo, Ross, Koh, Mickey, Ho, Liam Pock, Chan, Marieta, Niam, Madelaine, Soh, Melissa, Luah, Yen Hoon, Lim, Chwee Ming, Kaliaperumal, Nivashini, Au, Veonice B, Talib, Najwa Binte Said Nasir, Sng, Reina, Connolly, John E, Goh, Boon Cher, Schwarz, Herbert (2021-10-18). Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. CANCER IMMUNOLOGY IMMUNOTHERAPY 71 (6) : 1531-1543. ScholarBank@NUS Repository. https://doi.org/10.1007/s00262-021-03075-3 0340-7004 1432-0851 https://scholarbank.nus.edu.sg/handle/10635/239112 en SPRINGER Elements |
| institution |
National University of Singapore |
| building |
NUS Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NUS Library |
| collection |
ScholarBank@NUS |
| language |
English |
| topic |
Science & Technology Life Sciences & Biomedicine Oncology Immunology Nasopharyngeal carcinoma CD137L-DC Dendritic cell immunotherapy EBV Phase 1 clinical trial CD137 LIGAND T-CELLS LYMPHOCYTE-ACTIVATION PHASE-II MONOCYTE IMMUNOTHERAPY RECEPTOR MEMBER DIFFERENTIATION PROLIFERATION |
| spellingShingle |
Science & Technology Life Sciences & Biomedicine Oncology Immunology Nasopharyngeal carcinoma CD137L-DC Dendritic cell immunotherapy EBV Phase 1 clinical trial CD137 LIGAND T-CELLS LYMPHOCYTE-ACTIVATION PHASE-II MONOCYTE IMMUNOTHERAPY RECEPTOR MEMBER DIFFERENTIATION PROLIFERATION Nickles, Emily Dharmadhikari, Bhushan Li, Yating Walsh, Robert J Koh, Liang Piu Poon, Michelle Tan, Lip Kun Wang, Ling-Zhi Ang, Yvonne Asokumaran, Yugarajah Chong, Wan Qin Huang, Yiqing Loh, Kwok Seng Tay, Joshua Soo, Ross Koh, Mickey Ho, Liam Pock Chan, Marieta Niam, Madelaine Soh, Melissa Luah, Yen Hoon Lim, Chwee Ming Kaliaperumal, Nivashini Au, Veonice B Talib, Najwa Binte Said Nasir Sng, Reina Connolly, John E Goh, Boon Cher Schwarz, Herbert Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| description |
10.1007/s00262-021-03075-3 |
| author2 |
MEDICINE |
| author_facet |
MEDICINE Nickles, Emily Dharmadhikari, Bhushan Li, Yating Walsh, Robert J Koh, Liang Piu Poon, Michelle Tan, Lip Kun Wang, Ling-Zhi Ang, Yvonne Asokumaran, Yugarajah Chong, Wan Qin Huang, Yiqing Loh, Kwok Seng Tay, Joshua Soo, Ross Koh, Mickey Ho, Liam Pock Chan, Marieta Niam, Madelaine Soh, Melissa Luah, Yen Hoon Lim, Chwee Ming Kaliaperumal, Nivashini Au, Veonice B Talib, Najwa Binte Said Nasir Sng, Reina Connolly, John E Goh, Boon Cher Schwarz, Herbert |
| format |
Article |
| author |
Nickles, Emily Dharmadhikari, Bhushan Li, Yating Walsh, Robert J Koh, Liang Piu Poon, Michelle Tan, Lip Kun Wang, Ling-Zhi Ang, Yvonne Asokumaran, Yugarajah Chong, Wan Qin Huang, Yiqing Loh, Kwok Seng Tay, Joshua Soo, Ross Koh, Mickey Ho, Liam Pock Chan, Marieta Niam, Madelaine Soh, Melissa Luah, Yen Hoon Lim, Chwee Ming Kaliaperumal, Nivashini Au, Veonice B Talib, Najwa Binte Said Nasir Sng, Reina Connolly, John E Goh, Boon Cher Schwarz, Herbert |
| author_sort |
Nickles, Emily |
| title |
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| title_short |
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| title_full |
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| title_fullStr |
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| title_full_unstemmed |
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| title_sort |
dendritic cell therapy with cd137l-dc-ebv-vax in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit |
| publisher |
SPRINGER |
| publishDate |
2023 |
| url |
https://scholarbank.nus.edu.sg/handle/10635/239112 |
| _version_ |
1821203632421339136 |